Tumor-promoting inflammation and the avoidance of immune destruction are hallmarks of
cancer. While innate immune cells, such as neutrophils, monocytes, and macrophages, are …

Immune checkpoint inhibitors (ICIs) have demonstrated significant clinical impact in
improving overall survival of several malignancies associated with poor outcomes; however …

Background Pembrolizumab is the first-line standard of care for advanced non–small cell
lung cancer (NSCLC) with a PD-L1 tumour proportion score (TPS)≥ 50%. Eastern …

Background Hyperprogressive disease (HPD) during treatment with anti-programmed death-
1/programmed death-ligand 1 monoclonal antibodies has anecdotally been reported in …

Purpose The metabolic changes associated with cachexia–sarcopenia syndrome might
down-regulate antitumor immunity. We hypothesized that this syndrome reduces efficiency …

Malnutrition and muscle wasting are frequently reported in cancer patients, either linked to
the tumor itself or caused by oncologic therapies. Understanding the value of nutritional care …

Background PD-1/PD-L1 engagement and overexpression of galectin-3 (Gal-3) are critical
mechanisms of tumor-induced immune suppression that contribute to immunotherapy …

Secondary sarcopenia is defined as a decrease in muscle mass due to disease or
malnutrition. Several studies have reported that secondary sarcopenia is an indicator of …

Background Recent research suggests that baseline body mass index (BMI) is associated
with response to immunotherapy. In this study, we test the hypothesis that worsening …

Cancer cachexia is a complex metabolic syndrome characterized by involuntary skeletal
muscle loss and is associated with poor clinical outcome, decreased survival and negatively …